Compare MOVE & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOVE | MBRX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 8.6M |
| IPO Year | 2021 | 2016 |
| Metric | MOVE | MBRX |
|---|---|---|
| Price | $7.50 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 123.9K | ★ 631.2K |
| Earning Date | 03-19-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $1,460.71 | N/A |
| Revenue Next Year | $96.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.67 | $3.13 |
| 52 Week High | $59.90 | $91.25 |
| Indicator | MOVE | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 54.85 |
| Support Level | $7.30 | $3.13 |
| Resistance Level | $9.41 | $4.32 |
| Average True Range (ATR) | 1.04 | 0.37 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 8.27 | 78.60 |
Movano Inc is developing a platform to deliver purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. its initial commercial product in development is the Evie Ring, a wearable designed specifically for women. The Evie Ring combines health and wellness metrics to give a full picture of one's health, which includes resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.